Wound Care Biologics Market Analysis

  • Report ID: 6256
  • Published Date: Sep 17, 2025
  • Report Format: PDF, PPT

Wound Care Biologics Market Segmentation:

Wound Type Segment Analysis     

Ulcers segment is expected to capture wound care biologics market share of over 45% by 2035 owing to the rising incidence of chronic venous leg ulceration among people suffering from varicose veins. According to a study published by the Journal of Vascular Surgery in 2023, around 40% of the population globally has varicose veins, one of the most common chronic venous illnesses. Venous leg ulcers impact approximately 1% to 2% of the population, with the prevalence rising to 4% in individuals over 65.

Chronic ulcers, such as diabetic foot ulcers and venous ulcers, are a major health concern worldwide. Advanced therapeutics such as negative pressure wound therapy (NPWT) promotes the healing of these complicated and resistant wounds. Such treatments reduce hospital time and facilitates quicker transitions to outpatient care settings. The efficacy of wound care biologics in accelerating ulcer closure, lowering infection risks, and improving overall patient outcomes caters to market expansion.

Product Segment Analysis     

The biologic skin substitutes segment is estimated to expand at a staggering CAGR through 2035. The major factor in the expansion of the segment is the rising number of burn and trauma cases worldwide.

Burns due to fire, heat, or hot substances are the fourth most common form of civilian trauma worldwide, after road traffic accidents, falls, and interpersonal violence. It is estimated that between 7 and 12 million people sustain burn injuries for which medical attention is required. Biologic skin substitutes are therefore, in huge demand due to their ability to accelerate wound closure, reduce scarring and improve overall wound healing.

End-user Segment Analysis     

In wound care biologics market, hospitals segment is projected to hold revenue share of over 32% by the end of 2035. Hospitals remain the foremost sites for patients seeking wound treatment, particularly those that are severe or chronic. Hospitals have wound-care units with qualified health professionals who are skilled at using biologics to aid in proper wound healing and improve patient outcomes. High patient football and the expanding demand for improved wound care treatments in hospital settings add to the segment growth.

Our in-depth analysis of the global market includes the following segments:

          Product

  • Biologic Skin Substitutes
  • Topical Agents

          Wound Type

  • Ulcers
  • Surgical and Traumatic
  • Burns

          End-User

  • Hospitals
  • Ambulatory Surgery Centers (ASCs)
  • Burn Centers
  • Wound Clinics

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of wound care biologics is estimated at USD 2.18 billion.

The global wound care biologics market size crossed USD 2.08 billion in 2025 and is likely to register a CAGR of more than 5.3%, exceeding USD 3.49 billion revenue by 2035.

The North America wound care biologics market is anticipated to capture 45% share by 2035, driven by a high number of wound care procedures.

Key players in the market include Smith & Nephew, Molnlycke Health Care AB, Integra LifeSciences Corporation, Wright Medical Group N.V., MiMedx Group, Inc., Vericel Corporation, Anika Therapeutics, Osiris Therapeutics, Inc., Solsys Medical, LLC, Lavior Pharma Inc..
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos